51
|
Fang L, Lin Z, Liao Z, Jin O, Gu J. THU0385 SAFETY OF TOFACITINIB THERAPY IN HBSAG CARRIERS WITH ANKYLOSING SPONDYLITIS: A PROSPECTIVE STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Targeted synthetic DMARDs (ts-DMARDs) are becoming more available and affordable in developing countries, where the prevalence of hepatitis B virus (HBV) infection is still an important public health issue. The safety of ts-DMARDs therapy in terms of the reactivation of hepatitis B virus (HBV) infection need more concern. Rare data from a prospective study focus on the use of ts-DMARDs in patients with concurrent ankylosing spondylitis (AS) and HBV infection were available by now.Objectives:To evaluate the influence of tofacitinib on reactivation of HBV infection in HBsAg carriers with AS.Methods:In this 52 weeks observation, HBsAg carriers with active AS (BASDAI ≥ 4) despite failed treatment with at least two NSAIDs and sulfasalazine (for patients with persistent peripheral arthritis) were studied. Patients must be positive for HBsAg and have a normal liver function prior to study.All patients received therapy with tofacitinib (5mg twice daily). Entecavir were prescribed preventively regardless of individual viral load. Pre-existing NSAIDs and sulfasalazine were allowed. Liver enzymes (AST/ALT) and HBV viral load were monitored every 4 weeks. Increased viral load and abnormal liver function were managed according to expert opinion.Results:Eleven patients (9 male) were recruited. Eight patients had a baseline viral load >2000 copy/ml (group 1), and the other 3 patients had a viral load ≤ 2000 copy/ml (group 2). Two patients from group 1 discontinued tofacitinib at week 12 due to ineffectiveness, and both continued taking Entecavir for another 3 months after the discontinuation of tofacitinib.One patients (male, 26 years old) from group 1 underwent a mild increase of both ALT and AST (67 and 56 IU/L, respectively) at week 16, but no elevated viral load (2.1e3 copies/ml, baseline 2.8e3) or a HBV YMDD mutant was found. The tofacitinib treatment continued. After prescription of polyene phosphatidyl choline, the liver enzyme of this patient decreased to normal range in 4 weeks and remained normal throughout the study.No reactivation of hepatitis B was observed in patients from group 2.Conclusion:Tofacitinib treatment may be a safe and effective option for HBsAg carriers with AS refractory to traditional treatment. Prophylaxis strategy with effective anti-viral drugs is recommended.References:[1]Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis 2018; 77:780-2.Disclosure of Interests:None declared
Collapse
|
52
|
Jiang Y, Liao Z, Huang Y, Liang J, Xie Y, Wu J, Gu J. AB1301-HPR COMORBIDITIES AND FACTORS INFLUENCING RECURRENT GOUT ATTACK IN PATIENTS WITH GOUT: A CROSS-SECTIONAL STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Gout attack is characterized by painful arthritis, loss of function and reduced quality of life. Frequent gout attacks can exert negative an influence on gout management [1].Objectives:The objective was to identify the comorbidities of gout, to compare gender difference and to identify independent factors of multiple gout attacks.Methods:A cross-sectional study was performed to collect demographic, clinical variables, self-reported comorbidities, and relevant testing. Group comparison and correlation of serum uric acid (sUA) levels with other variables was performed. Univariate and multivariate logistic regression was used to detect independent risk factors of sUA.Results:653 gout patients were enrolled, including 553 (84.7%) males. The mean age was 48.3±15.8 years old, with a disease duration of 8.0±6.4 years. 170 (26.0%) patients had hypertension, and 57 (8.7%) had hyperlipidemia. Elevated total cholesterol (TC) was observed in 173 (26.5%) cases. 42 (37.1%) cases presented with increased triglycerides (TG) and 270 (41.3%) had increased low-density lipoprotein (LDL-C). Abnormalities including nephrolithiasis (29.4%), hydronephrosis (3.2%), and gallstones (11.9%) were detected in the patients who underwent ultrasound examination. Although female patients had a longer disease duration, they had lower levels of sUA, creatine and C-reactive protein (CRP). A positive correlation with sUA was found in TG and CRP (P<0.05) in female patients, which was not observed in males. Only gout duration (OR=1.406,P<0.001), sUA (OR=1.006,P<0.001) and LDL-C (OR=0.530,P=0.006) were independent factors of gout attack (>20 times).Conclusion:Comorbidity screening involving dyslipidemia is often neglected in gout patients. Gout duration and sUA level are risk factors of multiple gout attacks.References:[1]Wang Y, Yan S, Li C et al. Risk Factors for Gout Developed From Hyperuricemia in China: A Five-Year Prospective Cohort Study.Rheumatol Int. 2013; 3: 705-10.Table 1.Comparisons of clinical and laboratory variables between male and female patients with goutVariableMale (n=553)Female (n=100)pAge (years)47.7±15.951.3±14.50.040*BMI (kg/ m2)24.5 (22.0-27.0)23.3 (20.3-25.3)0.001*Gout duration (years)6.0 (3.0-11.0)9.5 (4.0-15.0)0.001*Gout attack times•≤5209 (37.5)33 (33.0)•6-1097 (17.5)22 (22.0)•11-2070 (12.7)22 (23.0)•>20177 (32.0)23 (23.0)ComorbidiesHypertension, n (%)138 (25.0)32 (32.0)0.140Coronary heart disease, n (%)57 (10.3)10 (10.0)0.926Fatty liver disease53 (9.6)4 (4.0)0.069Laboratory testing•ALT(U/L)25.0 (17.0-40.0)19.2 (14.6-29.0)0.003*•ALB(g/L)43.5±6.342.4±3.90.025*•TB (μmol/L)12.7 (9.0-17.3)14.5 (12.1-17.4)0.002*•BUN (mmol/L)4.85 (3.98-6.27)4.85 (3.91-4.82)0.588•Creatine (mmol/L)94.0 (81.4-108.1)73.8 (67.4-87.2)<0.001*•UA (μmol/L)528.4±141.1363.8±122.9<0.001*•Glucose (mmol/L)5.62±1.675.43±1.170.317•TC (mmol/L)5.05±1.155.09±1.100.726•TG (mmol/L)2.11±1.661.94±1.860.335•HDL-C (mmol/L)1.14±0.301.52±0.41<0.001*•LDL-C (mmol/L)3.25±0.973.39±0.920.182•ESR (mm/h)40.1±32.437.4±20.80.402•CRP (mg/L)28.0±40.310.5±18.6<0.001**p< 0.05; BMI: body mass index; sUA: serum uric acid; ALT: alanine aminotransferase; ALB: albumin; TB: Total bilirubin; BUN: blood urea nitrogen; UA: uric acid; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein; LDL-C: Low-density lipoprotein; ESR: erythrocyte sedimentation rate; CRP: C-reactive proteinAcknowledgments:None.Disclosure of Interests:None declared
Collapse
|
53
|
Zhao Q, Liu L, Liao Z, Pan Y, Liu J, Jiang X. Ethanol combined with coil embolisation for the treatment of arteriovenous malformations in a patient with Parkes Weber syndrome. Ann R Coll Surg Engl 2020; 102:e54-e56. [PMID: 31755731 PMCID: PMC7027421 DOI: 10.1308/rcsann.2019.0146] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/31/2019] [Indexed: 02/05/2023] Open
Abstract
Parkes Weber syndrome is a rare congenital condition of the vascular system with severe symptoms and life-threatening complications. The challenge is to manage the arteriovenous malformations, and there is no consensus on optimal treatment. We report the case of an 18-year-old woman with Parkes Weber syndrome who was treated with ethanol combined with coil embolisation at an early stage. After two sessions of embolisation, a significant devascularisation was achieved. No sign of recurrence was observed two years after the initial procedure. The patient's symptoms and signs were greatly relieved during the follow-up period. This case raises awareness of Parkes Weber syndrome and highlights the importance of timely intervention, as well as offering a promising therapeutic option for this condition.
Collapse
|
54
|
Liao Z, Li ZS. [Research and development of capsule endoscopy in the past two decades: age of adulthood, heart of establishment]. ZHONGHUA NEI KE ZA ZHI 2020; 59:89-94. [PMID: 32074680 DOI: 10.3760/cma.j.issn.0578-1426.2020.02.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
55
|
|
56
|
Chun S, Pezzi T, Schwartz D, Pisters K, Mohamed A, Welsh J, Chang J, Liao Z, Gandhi S, Byers L, Minsky B, Hahn S, Fuller C. PD01.20 Medicaid Outcome Inequalities in Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
57
|
Chun S, Liao Z, Jeter M, Chang J, Lin S, Komaki R, Guerrero T, Mayo R, Korah B, Koshy S, Heymach J, Koong A, Skinner H. P1.20 Metabolic Responses to Metformin in Early-Stage NSCLC Treated with Definitive Radiotherapy: Results of a Phase II Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
58
|
Lin S, Hobbs B, Thall P, Tidwell R, Wei X, Komaki R, Chang J, Chun S, Jeter M, Hahn S, Swisher S, Ajani J, Murphy M, Vaporciyan A, Mehran R, Koong A, Gandhi S, Hofstetter W, Liao Z, Mohan R. Results of a Phase II Randomized Trial of Proton Beam Therapy vs Intensity Modulated Radiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.08.030] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
59
|
Peng P, Chen Y, Han G, Meng R, Zhang S, Liao Z, Zhang Y, Gong J, Xiao C, Liu X, Zhang P, Zhang L, Xia S, Chu Q, Chen Y, Zhang L. MA01.09 Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.499] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
60
|
Lin S, Augustyn A, He J, Qiao Y, Liao Z, Raghavakaimal A, Gardner K, Heymach J, Tsao A, Adams D. MA08.01 Analysis of PD-L1 Expression on Circulating Stromal and Tumor Cells in Lung Cancer Patients Treated with Chemoradiation Therapy and Atezolizumab. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.556] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
61
|
Augustyn A, Adams D, He J, Qiao Y, Xu T, Liao Z, Raghavakaimal A, Gardner K, Tang C, Heymach J, Tsao A, Lin S. P2.01-93 Detection of Giant Cancer-Associated Macrophage-Like Cells After Concurrent Chemoimmunoradiation Is Associated with Poor Survival in NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
62
|
Li X, Xu T, Gomez D, Liao Z. Hemoglobin Level during Radiotherapy Predicts Survival Outcomes after Radiochemotherapy for Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
63
|
Deng W, Xu T, He J, Qiao Y, Liao Z, Lin S. The Value of Troponin T Level Change During Chemoradiation in Esophageal Cancer Patients. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
64
|
Nguyen Q, Chow E, Chun S, Komaki R, Liao Z, Fnu R, Szeto B, Hahn S, Fuller C, Moon B, Lin P, Bird J, Satcher R, Jeter M, O'Reilly M, Lewis V. Single-Fraction Stereotactic versus Conventional Multifraction Radiation for Predominantly Non-Spine Bone Metastases: A Randomized Phase II Trial. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
65
|
Moningi S, Nguyen Q, Lin S, Jeter M, O'Reilly M, Chang J, Chen A, Allen P, Lu C, Tsao A, Mohan R, Liao Z. Phase II Trial of Intensity-Modulated Photon or Scanning Beam Proton Therapy Both with Simultaneous Integrated Boost Dose Escalation to the Gross Tumor Volume with Concurrent Chemotherapy for Stage II/III Non-Small Cell Lung Cancer - Interim Analysis. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
66
|
Moding E, Nabet B, Liu Y, Chabon J, Chaudhuri A, Hui A, Binkley M, He J, Qiao Y, Xu T, Yao L, Gandhi S, Liao Z, Das M, Ramchandran K, Padda S, Neal J, Wakelee H, Gensheimer M, Loo B, Lin S, Alizadeh A, Diehn M. Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.610] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
67
|
Augustyn A, Adams D, He J, Qiao Y, Xu T, Raghavakaimal A, Liao Z, Amstutz P, Tang C, Lin S. Presence of Giant Circulating Cancer-Associated Macrophage-like Cells after Definitive Chemoradiation Predicts for Progression in Locally Advanced Non-Small Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
68
|
Fernandez J, Huber K, Webb C, Rouzard K, Tamura M, Wang Y, Liao Z, Sun P, Nie J, Zhang Z, Stock M, Stock J, Perez E. LB1113 TIRACLE™ and ACTIVITIS™: A novel anti-aging blend. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.06.079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
69
|
Pezzi T, Schwartz D, Mohamed A, Welsh J, Chang J, Liao Z, Hahn S, Fuller C, Chun S. The Impact of Medicaid Insurance on Treatment and Outcomes in Limited-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
70
|
Ajdari A, Shusharina N, Liao Z, Mohan R, Bortfeld T. Mid-Treatment [18]F-FDG PET Uptakes Can Predict Symptomatic Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
71
|
Palma G, Conson M, Xu T, Hahn S, Durante M, Mohan R, Liao Z, Cella L. Severe Radiation Induced Dermatitis after IMRT or Proton Therapy for Thoracic Cancer Patients. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
72
|
Jethwa K, Deng W, Gonuguntla K, Liao Z, Yoon H, Murphy M, Haddock M, Lin S, Hallemeier C. Multi-Institutional Evaluation of Curative Intent Chemoradiotherapy for Patients with Clinical T1N0 Esophageal Adenocarcinoma. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
73
|
Chang J, Zhu Z, Liao Z, Meng T, Zheng S, Cicuttini F, Winzenberg T, Wluka A, Jiang D, Han W, Ding C. A novel method for assessing proximal tibiofibular joint on MR images in patients with knee osteoarthritis. Osteoarthritis Cartilage 2018; 26:1675-1682. [PMID: 30195044 DOI: 10.1016/j.joca.2018.08.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 07/30/2018] [Accepted: 08/28/2018] [Indexed: 02/02/2023]
Abstract
OBJECTIVES To validate a method to measure the morphological parameters of the proximal tibiofibular joint (PTFJ) in patients with knee osteoarthritis (OA). METHODS 408 participants were examined in this cross-sectional subject-based study. We calculated the fibular contacting area of PTFJ (S) and its projection areas onto the horizontal plane (load-bearing area, Sτ), the sagittal plane (lateral stress-bolstering area, Sφ) and the coronal plane (posterior stress-bolstering area, Sυ). Joint space narrowing (JSN) and osteophyte was measured using radiographs. Cartilage defects, bone marrow lesions (BMLs) and cartilage volume were evaluated using magnetic resonance imaging (MRI). RESULTS The average PTFJ fibular contacting area was 2.4 cm2 (SD, ±0.7 cm2). Intra-observer and inter-observer reliabilities of measures of PTFJ morphological parameters were excellent (≥0.90). S, Sτ and Sφ were significantly associated with JSN in the medial tibiofemoral compartment (PR: 1.40, 95% CI 1.10-1.78; PR: 1.65, 95% CI 1.25-2.18 and PR: 0.53, 95% CI 0.29-0.97, respectively). There was a significantly positive association between S, Sτ and medial and/or femoral tibial cartilage defects. S, Sτ and Sυ were significantly and positively associated with medial and/or femoral tibial BMLs (PR: 1.36, 95% CI 1.12-1.64; PR: 1.47, 95% CI 1.17-1.83; and PR: 1.39, 95% CI 1.06-1.82, respectively) after adjustment. S and Sτ were significantly and negatively associated with medial tibial cartilage volume. CONCLUSIONS This novel method to assess the morphological parameters of PTFJ in MRI is reproducible. These parameters are associated with knee radiographic and MRI-based OA-related structural abnormalities, suggesting clinical construct validity. Its predictive validity needs to be examined in future longitudinal studies.
Collapse
|
74
|
Garant A, Whitaker T, Spears G, Harmsen W, Liu A, Routman D, Liao Z, Komaki R, Mehran R, Lester S, Haddock M, Hallemeier C, Lin S, Merrell K. A Multi-institutional Analysis of Dosimetric Predictors of Toxicity Following Trimodality Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
75
|
Lin S, He J, Qiao Y, Hofstetter W, Blum Murphy M, Komaki R, Liao Z, Gandhi S, Gomez D, Wistuba I, Tang C, Adams D. Detection of Circulating Giant Cancer Associated Macrophage like Cells During and after Radiation Therapy Is Associated with Disease Progression in Thoracic Cancers. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|